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INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal
stem cell disorder characterized by
myeloproliferation and by the presence of Phila-
delphia (Ph) chromosome.
Ph chromosome was the first cytogenetic
abnormality described in cancer.1 Later it was
shown that Ph was a balanced translocation be-
tween chromosomes 9 and 22. At a molecular
level, there is rearrangement of the BCR and ABL
genes with the function of codifying a fusion
protein with increased and deregulated tyrosine
kinase activity.2-3
With the diverse methods available today,
Ph-negative patients seem to have poorer sur-
vival and evolve more rapidly to blast crisis. How-
ever, some authors consider that these patients
could have a different disease.4
The usual method for detection of Ph is bone
marrow G-banding karyotyping. Around 90%
of the patients have the translocation detected
by this method. Half of the remaining patients
may present the rearrangement by fluorescent in
situ hybridization (FISH) or reverse transcriptase
polymerase chain reaction (PCR).4
Nowadays, CML treatment is done using
myelosuppressive drugs, but the only way to
achieve a cure is bone marrow transplantation
(BMT). However, this is possible only for those
that have an HLA-compatible donor and are
younger than the limiting age for the procedure.
Around 50 to 60% of the transplanted patients
are cured while the remaining ones relapse or die
due to complications.5
In the post-BMT period it is necessary to
check on the disappearance of the malignant
clone using sensitive methods, since the detec-
tion of possible residual disease may indicate the
need for additional therapy.
The present work aimed to compare the re-
sults of karyotyping and FISH at diagnosis and
after BMT for detection of residual disease.
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METHODS
Twelve patients with CML were studied at
diagnosis and one year after BMT. The aspirated
bone marrow was divided and placed into two
culture flasks with RPMI 1640 medium, pH 7.2,
20% fetal calf serum, 1% antibiotics and L-
glutamine (100mL). Colcemid was added dur-
ing the last 60 minutes followed by hypotonic
treatment with KCl (0.075 mol/L) for 20 min
and fixation with Carnoy´s fixative (methanol
and acetic acid, 3:1) repeated 4 times. The slides
were banded for trypsin G-banding (GTG). Ten
metaphases from each culture were analyzed and
chromosomal abnormalities described in accord-
ance with ISCN 1995.6
A portion of the cell pellets stored in
Carnoy´s fixative was separated for FISH. This
material was centrifuged again and resuspended;
the slides were made using cytospin (Incibrás).
FISH was made following the probe supplier’s
instructions (BCR/ABL- Oncor). The slides were
analyzed through a fluorescent microscope (Ol-
ympus BMX60) with DAPI, rhodamine, FITC
and triple bandpass filters (Chroma Technology).
The best images were captured via a CCD cam-
era mounted on the microscope and linked to a
computer with karyotyping and FISH software
(CytoVision - Applied Image). Slides showing
more than 50% cells with fluorescent dots were
selected for analysis. From each slide, at least 200
cells were counted, all of them isolated to avoid
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CONTEXT: Identification of Philadelphia chromosome or
BCR/ABL gene rearrangement in chronic myeloid
leukemia is important at diagnosis as well as after
treatment.
OBJECTIVE: To compare the results of karyotyping us-
ing fluorescent in-situ hybridization (FISH) upon di-
agnosis and 1 year after bone marrow transplanta-
tion in 12 patients.
TYPE OF STUDY: Diagnostic test and residual disease
detection.
SETTING: Hematology and Hemotherapy Department,
Federal University of São Paulo/Escola Paulista de
Medicina, São Paulo, Brazil.
SAMPLE: 12 patients with chronic myeloid leukemia at
diagnosis and 1 year after bone marrow transplan-
tation.
DIAGNOSTIC TEST: Karyotyping was done in the usual
way and the BCR/ABL gene-specific probe was used
for FISH.
MAIN MEASUREMENTS: Disease at diagnosis and re-
sidual.
RESULTS: At diagnosis, 10 patients presented
t(9;22)(q34.1;q11) as well as positive FISH. Two
cases did not have metaphases but FISH was posi-
tive. After bone marrow transplantation, 8 patients
presented normal karyotype, 1 had persistence of
identifiable Philadelphia chromosome and 3 had
no metaphases. Two cases showed complete chi-
mera and 2 had donor and host cells simultane-
ously. FISH was possible in all cases after bone
marrow transplantation and confirmed the
persistence of identifiable Philadelphia chromosome
clone in one patient, and identified another that did
not present metaphases for analysis. Cases that
showed mixed chimera in karyotype were negative
for BCR/ABL by FISH.
CONCLUSION: The applicability of FISH is clear, par-
ticularly for residual disease detection. Classical and
molecular cytogenetics are complementary methods.
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overlapping signals. Red dots (rhodamine) cor-
responded to the ABL (9q34.1) gene and green
dots (fluorescein) to the BCR (22q11) gene, so
when one cell with two isolated red and green
dots was seen, it was counted as normal, without
rearrangement. When a cell with one isolated red
dot, one isolated green dot and one fused red
and green signal was seen, this was considered as
presenting rearrangement (Figure). All slides were
analyzed by at least two observers. As the differ-
ence between the observers presented small
variation the results were summed and averaged.
Five samples of normal marrow donors served as
a control group. The controls provided an esti-
mation of overall hybridization quality of the test
material. Using the method of “rate obtained in
the control samples plus two standard
deviations”, the cutoff level for rearrangement was
established as 10%.
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RESULTS
Table shows patients’ sex, age, date of diag-
nosis, karyotype at diagnosis, FISH at diagnosis,
date of BMT, donor’s sex, and karyotype and
FISH at one year after BMT.
It was possible to compare the results of
karyotyping and FISH at diagnosis and one year
after transplantation. At diagnosis, 10 patients
presented Ph chromosome by cytogenetics and
two (11 and 12) did not show metaphases that
could be studied. FISH was positive in all except
2 (6 and 8), whose samples did not have enough
cells for analysis. Cases that did not present cy-
togenetic results (11 and 12) presented positive
BCR/ABL rearrangement by FISH.
The percentage of cells with BCR/ABL re-
arrangement by FISH at diagnosis varied from
66 to 98%, with a mean of 81.25%.
One year after transplantation, karyotyping
was not possible in 3 cases (3, 6 and 9) due to
lack of metaphases. In eight cases (2, 4, 5, 7, 8,
10, 11 and 12), the karyotype was normal while
one patient (1) had persistence of the Ph chro-
mosome. Two cases (4 and 8) showed complete
chimera, as the karyotype changed to the do-
nor’s pattern (different sexes). In the remaining
cases in which donor and receptor had the same
sex (2, 5, 7, 10 and 11), Ph was not observed.
Two cases (5 and 12) presented two cell lines,
i.e. donor and host residual cells.
FISH at one year after transplantation was
possible in all cases, even in those that did not
present metaphases for karyotyping. Case 1 had
around 30% of Ph-positive cells, in karyotype as
well as FISH. Case 9 had clinical and
hematological relapse, a karyotype without
metaphases and FISH with 94% of cells with
BCR/ABL rearrangement, confirming disease
relapse in the chronic phase.
In cases whose karyotype showed persistence
of host residual cells even at low percentages,
FISH showed absence of rearrangement.
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DISCUSSION
Determination of the presence of the Ph
chromosome by karyotyping at diagnosis is nec-
essary as part of differential diagnosis and as prog-
nosis. This is an entirely manual test with a turna-
round time of 7 to 15 days. Cheaper and faster
methods would be ideal. FISH is a feasible tech-
nique, faster (usually 48 hrs) but still expensive
due to the cost of probes.
Would there be advantages in replacing
karyotype detection of Ph by FISH at diagnosis?
The initial answer is no, since karyotyping and
FISH were equal, as shown in the present work,
except for the fact that FISH was faster. In cases
that did not present metaphases by karyotyping,
FISH was extremely useful in providing a result.
In daily practice, FISH can be very helpful since
it may be done on the same sample used for
karyotyping without the need for new marrow
aspiration. Another reason for continuing with
classical cytogenetics at diagnosis is the possibil-
ity of detecting additional karyotype abnormali-
ties or variant Ph. This was not seen in the present
sample but has been in others.7
After treatment, methods that promptly, sen-
sitively and reliably detect residual disease are
chosen. Karyotyping has been the classical ideal,
but more sensitive techniques may tend to re-
place it. This in part due to the low sensitivity
Table. Description of sex, age, date of diagnosis, karyotype and FISH at diagnosis, donor’s sex, and karyotyping and FISH at one year after BMT
Case Sex Age Diagnosis Donor sex                                    1 year after BMT
Date  Karyotype  Fish Karyotype Fish
1 F 25  7/92 46,XX,t(9;22)(q34.1;q11)[20] 95% M 46,XX,t(9;22)[6]/46,XY[13] 25%
2 M 29 11/93 46,XY,t(9;22)(q34.1;q11)[20] 62.5% M 46,XY[17]  3%
3 F 20  6/93 46,XX,t(9;22)(q34.1;q11)[20] 89% F Without metaphases  6%
4 M 42 10/94 46,XY,t(9;22)(q34.1;q11)[20] 76% F 46,XX[15]  7%
5 F 14  4/97 46,XX,t(9;22)(q34.1;q11)[20] 92% M 46,XY[16]/46,XX[1]  6%
6 M 30 10/94 46,XY,t(9;22)(q34.1;q11)[20] WM M Without metaphases  7%
7 M 26  4/97 46,XY,t(9;22)(q34.1;q11)[20] 66% M 46,XY[15]  9%
8 M 26 10/96 46,XY,t(9;22)(q34.1;q11)[20] WM F 46,XX[19] 10%
9 M 23 10/96 46,XY,t(9;22)(q34.1;q11)[20] 95% M Without metaphases 94%
10 M 42  8/96 46,XY,t(9;22)(q34.1;q11)[20] 98% M 46,XY[20]  5%
11 F 33  1/96 Without metaphases 71% F 46,XX[15]  6%
12 F 21  9/96 Without metaphases 68% M 46,XY[19]/46,XX[1] 8.5%
M= male, F= female. WM = without material.
Figure. Image of interphase FISH with BCR/ABL probe.
D - ABL gene
* - BCR
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index of karyotyping, since usually 20 to 25
metaphases are studied and in the post BMT
period, when the patient is receiving myelotoxic
drugs, there may not be enough metaphases for
analysis. The FISH technique is especially valu-
able in these situations, as it is more sensitive even
though it is faster. RT-PCR is still more sensitive
but its clinical meaning has to be clarified.5
In the present work the BCR/ABL rearrange-
ment was demonstrated one year after BMT in
one patient (case 9) whose karyotyping was un-
successful. Similarly, another case (case 1) that
had persistence of Ph in karyotyping and has al-
ready been discussed elsewhere,8 presented a more
confident count in 200 interphases using FISH.
This type of information given by FISH is already
well known and appreciated.9
Cases in which a double population of cells is
observed by karyotyping, i.e. donor and host cells,
could indicate that residual cloning was not being
seen since karyotype sensibility was low. FISH al-
lowed us to conclude that such cases had mosaic
without residual disease, at least at the sensitivity
level of FISH, and that these data were compatible
with clinical aspects. This situation had been ob-
served before in a patient that had 40% of host cells
persisting for longer after BMT but with negative
PCR and FISH for BCR/ABL rearrangement.10
These data confirm the impression that there may
be mosaic without relapse.11 One year after BMT,
Polka et al.12 also detected mixed chimera with host
residual cells varying from 0.2 to 90%.
The percentage of cells with rearrangement
seen using FISH at diagnosis varied from 66 to
98%. Other authors have described levels from
30 to 98% but usually above 77 to 88%.9,13 Some
cases presented a low percentage of positive
interphases due to a low hybridization index but
still within acceptable limits (more than 50% of
cells with hybridization).
FISH allows later study using stored samples
that is valuable. The fact that fixed cells were be-
ing utilized was useful in this work, although there
were some limitations (cases 6 and 8). Many sam-
ples from other patients that fitted the aims of this
work were not included, often because the stored
material was not in an adequate condition or there
were not enough interphases for analysis.
After treatment, some patients presented lev-
els very close to normality (case 7 and 8). These
were reevaluated by PCR and until now have
remained negative. Periodic examination will al-
low detection of residual mass alterations.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
CONCLUSION
It was possible to compare the two methods
and it is clear that FISH has a well-defined use.
FISH and karyotyping are not mutually exclu-
sive methods but complementary.
CONTEXTO: Na leucemia mielóide crônica, a
detecção do cromossomo Philadelphia ou o
rearranjo gênico BCR/ABL é importante tanto
ao diagnóstico como após o tratamento.
OBJETIVO: Comparar os resultados do cariótipo
com a hibridação in situ por fluorescência ao
diagnóstico e, após um ano de transplante de
medula óssea, em 12 pacientes com leucemia
mielóide crônica.
TIPO DE ESTUDO: Teste diagnóstico e detecção
de doença residual.
LOCAL: Disciplina de Hematologia e Hemoterapia
da Universidade de São Paulo/Escola Paulista
de Medicina.
AMOSTRA: 12 pacientes com leucemia mielóide
crônica ao diagnóstico e um ano após
transplante de medula óssea.
TESTE DIAGNÓSTICO: A análise do cariótipo
(forma clássica) e a hibridação in situ por
fluorescência com a sonda específica para os
genes BCR/ABL.
VARIÁVEIS ESTUDADAS:  Doença ao
diagnóstico e residual.
RESULTADOS: Ao diagnóstico, 10 pacientes
apresentaram t(9;22)(q34.1;q11) no cariótipo
assim como pela hibridação in situ por
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
RESUMO
fluorescência. Dois casos em que na citogenética
não havia mitoses, apresentaram rearranjo pela
hibridação in situ por fluorescência. Após o
transplante de medula óssea, o cariótipo
mostrou ausência do cromossomo Philadelphia
em 8 casos, persistência em um e ausência de
metáfases em três. Em dois casos havia quimera
completa e em outros dois havia concomitância
de células do doador e do receptor. A hibridação
in situ por fluorescência foi possível em todos
os casos após o transplante de medula óssea,
confirmando a persistência do clone
cromossomo Philadelphia num paciente em
que o cariótipo também havia mostrado e
identificando noutro em que não havia
metáfases. Os casos de quimera mista foram
negativos para BCR/ABL pela hibridação in
situ por fluorescência.
CONCLUSÃO: Ficou evidente a aplicabilidade da
hibridação in situ por fluorescência,
particularmente na detecção de doença residual.
A citogenética clássica e a molecular são
métodos complementares.
PALAVRAS-CHAVE: Genes BCR/ABL. Leucemia
mielóde crônica. Hibridação in situ por
fluorescência. Leucemia mielóide crônica.
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